The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram
详细信息 查看全文
- 作者：Christian Schmidta ; Judith Leibigera ; b ; Markus Fendta ; c ; markus.fendt@med.ovgu.de" class="auth_mail" title="E-mail the corresponding author
- 关键词：EDS ; excessive daytime sleepiness ; EEG ; electroencephalography ; EMG ; electromyography ; NERI ; norepinephrine reuptake inhibitors ; REM ; rapid eye movements ; SSRI ; serotonin reuptake inhibitor
- 刊名：Behavioural Brain Research
- 出版年：2016
- 出版时间：15 July 2016
- 年：2016
- 卷：308
- 期：Complete
- 页码：205-210
- 全文大小：1087 K
文摘
- •
Orexin-deficient mice were used to study treatments’ effects on narcoleptic episodes.
- •
Reboxetine (≥0.55 mg/kg) and escitalopram (≥3.0 mg/kg) reduced narcoleptic episodes.
- •
Cirazoline and prazosin did not significantly affect narcoleptic episodes.
- •
That is, norepinephrine reuptake inhibitors (NERI) were most potent.
- •
This argues for the use of NERIs in narcolepsy treatment.